Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics' Q1 Revenues Rise 8 Percent

NEW YORK (GenomeWeb News) – Strategic Diagnostics yesterday reported first-quarter revenue growth of 8 percent and swung from a profit to a slight loss.
 
For the three-month period ended March 31, the Newark, Del.-based firm reported revenues of $7.2 million, up from $6.6 million in the first quarter of 2007. The firm said that primary growth drivers for the quarter were its food pathogen product sales, which climbed 36 percent year over year, and its antibody products, which increased 15 percent.
 
Strategic Diagnostics posted a net loss of $12,000, or $.00 per share, versus a profit of $490,000, or $.02 per share, for the first quarter of 2007.
 
The firm’s R&D expenses rose 35 percent to $940,000 from $697,000 year over year, while its SG&A costs increased 18.5 percent to $3.2 million from $2.7 million.
 
Strategic Diagnostics finished the quarter with $12.5 million in cash and cash equivalents.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.